⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070518 | 0.87 | — | — | |
| SCHEMBL14669343 | 0.65 | — | — | |
| SCHEMBL8133649 | 0.65 | — | — | |
| SCHEMBL3620017 | 0.64 | — | — | |
| SCHEMBL3620019 | 0.64 | — | — | |
| SCHEMBL22609089 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL21519507 | 0.62 | — | — | |
| SCHEMBL13510589 | 0.60 | — | — | |
| SCHEMBL13066318 | 0.58 | — | — | |
| SCHEMBL11827604 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285279-A1 | BIODEGRADABLE ALPHA-2 AGONIST POLYMERIC IMPLANTS AND THERAPEUTIC USES THEREOF | ALLERGAN, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230285279-A1 | BIODEGRADABLE ALPHA-2 AGONIST POLYMERIC IMPLANTS AND THERAPEUTIC USES THEREOF | ALLERGAN, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-3953363-B1 | NEW PHOSPHINIMIDE CATALYSTS FOR OLEFIN POLYMERIZATION | NOVA CHEM INT SA (CH) | 2023-06-07 | — | — | EP | disclosed |
| US-20220162242-A1 | NEW PHOSPHINIMIDE CATALYSTS FOR OLEFIN POLYMERIZATION | NOVA CHEMICALS (INTERNATIONAL) S.A. (CH) | 2022-05-26 | — | — | US | disclosed |
| US-20210251961-A1 | COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING SAME | ALLERGAN INC (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210161809-A1 | BIODEGRADABLE ALPHA-2 AGONIST POLYMERIC IMPLANTS AND THERAPEUTIC USES THEREOF | ALLERGAN INC (US) | 2021-06-03 | — | — | US | disclosed |
| US-10842739-B2 | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof | ALLERGAN, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200069578-A1 | BIODEGRADABLE ALPHA-2 AGONIST POLYMERIC IMPLANTS AND THERAPEUTIC USES THEREOF | ALLERGAN, INC. | 2020-03-05 | — | — | US | disclosed |
| US-10471004-B2 | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof | ALLERGAN, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20080118547-A1 | Associated with diabetes; implanting an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer matrix; hypotensive agents, antiischemic agents | ALLERGAN, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1644343-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |